Lotus Eye Hospital & Institute Ltd.
BSE: 532998 | Sector: Health care |
NSE: LOTUSEYE | ISIN Code: INE947I01017 |
BSE 00:00 | 27 May | 47.90 |
-1.75 (-3.52%) |
OPEN
48.00 |
HIGH
52.90 |
LOW
47.85 |
NSE 00:00 | 27 May | 47.85 |
-1.25 (-2.55%) |
OPEN
48.50 |
HIGH
49.10 |
LOW
47.55 |
OPEN | 48.00 |
PREVIOUS CLOSE | 49.65 |
VOLUME | 1135 |
52-Week high | 74.50 |
52-Week low | 38.65 |
P/E | 33.26 |
Mkt Cap.(Rs cr) | 100 |
Buy Price | 0.00 |
Buy Qty | 0.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
Lotus Eye Hospital & Institute Ltd. (LOTUSEYE) - Net Profit
Net Profit
COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Profit (Rs crore) |
Aurobindo Pharma | 529.60 | -5.90 | -1.10 | 3112.91 |
Cipla | 966.30 | 1.90 | 0.20 | 2468.28 |
Dr Reddy's Labs | 4392.00 | 84.75 | 1.97 | 2186.40 |
Sun Pharma.Inds. | 903.95 | 3.40 | 0.38 | 2139.70 |
Divi's Lab. | 3514.45 | 65.30 | 1.89 | 1954.72 |
Alkem Lab | 3042.05 | 17.70 | 0.59 | 1685.08 |
Glenmark Pharma. | 398.05 | 4.45 | 1.13 | 1649.45 |
Zydus Lifesci. | 373.65 | 0.80 | 0.21 | 1476.20 |
Lupin | 606.15 | 5.40 | 0.90 | 1258.62 |
Alembic Pharma | 733.45 | -5.20 | -0.70 | 1175.39 |
Ipca Labs. | 901.85 | -15.30 | -1.67 | 1140.77 |
Torrent Pharma. | 2939.85 | 38.95 | 1.34 | 1137.85 |
Gland Pharma | 2906.70 | 53.45 | 1.87 | 997.01 |
Laurus Labs | 566.60 | 7.40 | 1.32 | 956.11 |
Sanofi India | 6518.45 | -16.35 | -0.25 | 944.40 |
Abbott India | 17950.15 | 251.30 | 1.42 | 690.69 |
Ajanta Pharma | 1723.60 | -4.70 | -0.27 | 675.64 |
Wockhardt | 267.65 | 4.70 | 1.79 | 593.29 |
Granules India | 266.60 | 8.00 | 3.09 | 552.78 |
Pfizer | 4269.00 | 21.05 | 0.50 | 497.61 |
Quick Links for Lotus Eye Hospital & Institute:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices